Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVAnT1A anti-viral prevention trial for type 1 diabetes autoimmunity
2023-507348-35-00Phase 4Authorised
- Sponsor
- Klinikum rechts der Isar
- Start
- May 2024
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 7
01
Overview
Phase 4, randomised, double-blind trial of raxtozinameran and sodium chloride in diabetes mellitus type 1 (T1D) (2 arms), sponsored by Klinikum rechts der Isar. Primary endpoint: Time to persistent confirmed islet autoantibodies or type 1 diabetes. Planned start May 2024; status: authorised.
02
Drugs
raxtozinameransodium chloride
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2023-507348-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507348-35-00.